Health Economics Review最新文献

筛选
英文 中文
Data-driven reweighting of the Charlson and Elixhauser comorbidity indices using German claims data: development for in-hospital mortality only, external validation across clinical and health-economic outcomes. 使用德国索赔数据对Charlson和Elixhauser合并症指数进行数据驱动的重新加权:仅针对住院死亡率的开发,跨临床和健康经济结果的外部验证。
IF 3.4 3区 经济学
Health Economics Review Pub Date : 2026-10-27 DOI: 10.1186/s13561-026-00888-9
Klaus Kaier, Derek Hazard, Adrian Heidenreich, Alexander Maier, Dirk Westermann, Constantin von Zur Mühlen, Vera Oettinger
{"title":"Data-driven reweighting of the Charlson and Elixhauser comorbidity indices using German claims data: development for in-hospital mortality only, external validation across clinical and health-economic outcomes.","authors":"Klaus Kaier, Derek Hazard, Adrian Heidenreich, Alexander Maier, Dirk Westermann, Constantin von Zur Mühlen, Vera Oettinger","doi":"10.1186/s13561-026-00888-9","DOIUrl":"10.1186/s13561-026-00888-9","url":null,"abstract":"<p><strong>Background: </strong>Comorbidity scores such as the Charlson and Elixhauser indices are widely used for risk adjustment in health-economic and clinical outcomes research. Yet the existing weighting schemes, originally designed for mortality prediction, may no longer reflect today's patient populations or perform equally well across diverse outcomes. This study aimed to reweight both indices using a data-driven approach and to evaluate their predictive validity for multiple clinical and health-economic outcomes.</p><p><strong>Methods: </strong>Using administrative data from a large tertiary care teaching hospital in Germany (N = 198,819 hospitalizations), we applied adaptive lasso regression to recalibrate the Charlson (Deyo weights) and Elixhauser (van Walraven weights) comorbidity indices. Reweighting was performed for in-hospital mortality as the development endpoint. Penalized coefficients were converted into integer-based weights. Model performance was assessed for three dichotomous endpoints (in-hospital mortality, severe bleeding, prolonged mechanical ventilation) and two continuous outcomes (length of hospital stay, total reimbursement). External validation was performed in three independent cohorts: Elective endometrial cancer (N = 85,204), interventional left atrial appendage closure (N = 28,039), and emergency ST-elevation myocardial infarction (STEMI; N = 248,062). AUC, R², and RMSE were used as complementary measures of discrimination and predictive accuracy. Pooled relative improvements of AUC, R², and RMSE across the three validation cohorts was calculated using random effects meta-analyses.</p><p><strong>Results: </strong>Reweighting consistently improved predictive performance across endpoints and cohorts, with modest absolute gains for in-hospital mortality and more pronounced gains for severe bleeding and continuous outcomes. When analysing in-hospital mortality in the three validation cohorts, the reweighted Charlson improved AUC from 0.679 to 0.714 in left atrial appendage closure, 0.588 to 0.594 in STEMI, and 0.798 to 0.810 in endometrial cancer (pooled relative increase: 2.05% [95% CI 0.56-3.53]); the reweighted Elixhauser showed larger gains, particularly in STEMI (0.708 to 0.766) and left atrial appendage closure (0.780 to 0.818; pooled relative increase: 4.86% [0.07-9.65]). The Elixhauser reweighting demonstrated consistently larger gains for severe bleeding (pooled AUC increase: 6.57% [4.23-8.92]). For continuous outcomes, the reweighted Elixhauser index yielded the largest gains in explained variance, with a pooled relative R² increase of 39.66% [33.72-45.60] for total reimbursement. Corresponding reductions in RMSE were modest and often not statistically significant.</p><p><strong>Conclusions: </strong>Adaptive lasso reweighting consistently enhances the predictive validity of the Charlson and Elixhauser indices across both clinical and health-economic endpoints. Our multi-endpoint evaluation shows consisten","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"16 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13721275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149301087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Families caring for children and adolescents with rare disease: a health economic evaluation of face-to-face and online psychosocial support intervention of the randomized controlled CARE-FAM-NET study. 照顾患有罕见疾病的儿童和青少年的家庭:随机对照CARE-FAM-NET研究中面对面和在线社会心理支持干预的健康经济评估
IF 3.4 3区 经济学
Health Economics Review Pub Date : 2026-10-26 DOI: 10.1186/s13561-026-00883-0
Nicolas Pardey, Kristine Kreis, Anna Leidger, Johannes Boettcher, Jonas Denecke, Sara Soeiro Gomes, Ania C Muntau, Anne Daubmann, Ann-Kathrin Ozga, Antonia Zapf, Karl Wegscheider, Miriam Rassenhofer, Jörg Fegert, Dunja Tutus, Ursula Marschall, Stefanie Schellhammer, Sophia Rocabado, Thomas Krull, Anja Wadeck, Udo Schneider, Steve Hüttmann, Michél Henkel, Johann-Matthias von der Schulenburg, Silke Wiegand-Grefe, Jan Zeidler
{"title":"Families caring for children and adolescents with rare disease: a health economic evaluation of face-to-face and online psychosocial support intervention of the randomized controlled CARE-FAM-NET study.","authors":"Nicolas Pardey, Kristine Kreis, Anna Leidger, Johannes Boettcher, Jonas Denecke, Sara Soeiro Gomes, Ania C Muntau, Anne Daubmann, Ann-Kathrin Ozga, Antonia Zapf, Karl Wegscheider, Miriam Rassenhofer, Jörg Fegert, Dunja Tutus, Ursula Marschall, Stefanie Schellhammer, Sophia Rocabado, Thomas Krull, Anja Wadeck, Udo Schneider, Steve Hüttmann, Michél Henkel, Johann-Matthias von der Schulenburg, Silke Wiegand-Grefe, Jan Zeidler","doi":"10.1186/s13561-026-00883-0","DOIUrl":"10.1186/s13561-026-00883-0","url":null,"abstract":"<p><strong>Background: </strong>Parents caring for children with rare diseases often experience a reduced Health-Related Quality of Life (HRQoL). This study addresses the growing need for therapeutic support by evaluating two innovative forms of care: CARE-FAM (CF) and a web-based program (WEP) WEP-CARE (WC). CF is a psychodynamic-psychosocial intervention with eight sessions per family over six months, aiming to improve mental health, HRQoL, and satisfaction of all family members. WC is an online intervention leveraging cognitive-behavioral writing therapy principles to achieve the same objectives. The aim of this study was to evaluate the incremental cost per quality-adjusted life year (QALY) gained for CF, WC and their combination (CF + WC) compared with the control group (CG), on a per-parent basis, over an 18-month time horizon from the German statutory health insurance (SHI) payer perspective.</p><p><strong>Methods: </strong>Children Affected by Rare disease and Their Families - Research Network (CARE-FAM-Net) is a 2 × 2 factorial, multicenter randomized controlled study conducted across 17 psychiatric hospitals in Germany with three intervention groups (CF, WC, CF + WC) and a control group. Cost evaluations utilized claims data from seven SHI funds, reflecting the SHI payer perspective, while QALYs were calculated using the EQ-5D-3 L score at four points over an 18-month time horizon. The unit of analysis was the individual parent, therefore all costs and QALYs were estimated on a per-parent basis. The primary analysis used the intention-to-treat statutory health insurance (ITT-SHI) population. Missing data were addressed through multiple imputation by chained equations with predictive mean matching, generating 20 imputed datasets that were combined using Rubin's rules. Within-family correlation was accounted for in the statistical analyses. Numerical incremental cost-effectiveness ratios (ICERs) were reported where appropriate, and non-parametric family-cluster bootstrapping was performed to estimate statistical uncertainty. The sensitivity analysis used a restricted population. Costs and QALYs were discounted at a rate of 3%.</p><p><strong>Results: </strong>The primary ITT-SHI analysis included 653 participants, with a mean age of 39.4 years (SD 7.2), and 396 (60.6%) were female. Unadjusted mean annual discounted costs per parent were €4476 (SE €631) for CG, €3539 (SE €755) for CF, €3970 (SE €1249) for WC and €5518 (SE €1850) for CF + WC. Unadjusted mean annual discounted QALYs per parent were 0.9144 (SE 0.0079) for CG, 0.9215 (SE 0.0097) for CF, 0.9287 (SE 0.0074) for WC and 0.9313 (SE 0.0075) for CF + WC. Based on the incremental mean costs and baseline-adjusted QALY differences, CF and WC dominated CG, whereas CF + WC had an ICER of €109,371 per QALY gained. However, none of the between-group differences in costs or baseline-adjusted QALYs were statistically significant. At a willingness-to-pay (WTP) of €50,000 per QALY, the probabili","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"16 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13721576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Budget impact analysis of implementing point-of-care molecular testing for influenza A&B and RSV in Saudi older adult patients across hospital and home-care settings. 在医院和家庭护理环境中对沙特老年患者实施甲型和乙型流感和呼吸道合胞病毒定点护理分子检测的预算影响分析
IF 3.4 3区 经济学
Health Economics Review Pub Date : 2026-10-07 DOI: 10.1186/s13561-026-00872-3
Walid Alkeridy, Khulud Alharbi, Amal Abuhamar, Abdullah Alarifi, Najim Z Alshaharni, Sulafa Alrkabi, Gihan Hamdy Elsisi, Saad M Alsaad
{"title":"Budget impact analysis of implementing point-of-care molecular testing for influenza A&B and RSV in Saudi older adult patients across hospital and home-care settings.","authors":"Walid Alkeridy, Khulud Alharbi, Amal Abuhamar, Abdullah Alarifi, Najim Z Alshaharni, Sulafa Alrkabi, Gihan Hamdy Elsisi, Saad M Alsaad","doi":"10.1186/s13561-026-00872-3","DOIUrl":"https://doi.org/10.1186/s13561-026-00872-3","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of our study is to compare the economic impact of adopting the molecular point-of-care test (mPOCT) for influenza A&B and RSV with current clinical judgment in Saudi Arabia, in both hospital-based and home care older adults.</p><p><strong>Methodology: </strong>A static Budget Impact Analysis (BIA) was developed in Microsoft Excel to evaluate the clinical and economic consequences of adopting mPOCT for influenza A&B and RSV testing among prevalent older adult patients in Saudi Arabia. The model adopted the perspective of the Saudi healthcare system over a one-season horizon, comparing two diagnostic strategies: current practice based on clinical judgement and a future scenario using mPOCT in both older-adult-friendly hospitals and homecare settings. Parallel decision-tree structures were constructed for influenza and RSV, incorporating test accuracy, diagnostic outcomes, treatment pathways, hospitalization requirements, and mortality. Costs included diagnostics, staff time, outpatient visits, hospital stays, medications, and resources used for complications and inappropriate antibiotic prescribing. Epidemiologic, clinical, and cost inputs were derived from published evidence and supplemented with Saudi-specific data where available. A deterministic sensitivity analysis varied cost parameters ± 20% and clinical parameters across published confidence intervals.</p><p><strong>Results: </strong>Adoption of the mPOCT was associated with substantial cost savings across all modeled (hospital and homecare settings) older adults. For Influenza A&B, total costs decreased from SAR 57,858,038 to SAR 26,933,837 in hospital settings and from SAR 13,254,535 to SAR 7,974,232 in homecare, yielding savings of SAR 30,924,201 and SAR 5,280,303, respectively. For RSV, hospital costs fell from SAR 40,640,192 to SAR 20,706,660, and homecare costs from SAR 9,157,462 to SAR 5,988,728, saving SAR 19,933,531 and SAR 3,168,733, respectively. Overall, mPOCT produced SAR 59,306,768 in combined savings, demonstrating strong economic value for respiratory infection management in Saudi Arabia.</p><p><strong>Conclusion: </strong>This BIA demonstrates that implementing the mPOCT platform for influenza A&B and RSV in Saudi Arabia may provide substantial clinical and economic value, particularly for high-risk older adults. By enabling rapid and accurate diagnosis at both hospital and homecare entry points, mPOCT may significantly reduce false negatives, mitigates progression to severe lower respiratory tract infections, and decreases unnecessary antiviral and antibiotic use. These improvements could translate into major reductions in healthcare utilization, including ward and ICU admissions, and may generate considerable cost savings across a single respiratory season.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"16 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13660157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149185083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The effect of case-based payment reform on hospitalization rates: evidence from China. 基于案例的支付改革对住院率的影响:来自中国的证据。
IF 3.4 3区 经济学
Health Economics Review Pub Date : 2026-10-06 DOI: 10.1186/s13561-026-00868-z
Miao Yu, Xiaojia Zhu
{"title":"The effect of case-based payment reform on hospitalization rates: evidence from China.","authors":"Miao Yu, Xiaojia Zhu","doi":"10.1186/s13561-026-00868-z","DOIUrl":"10.1186/s13561-026-00868-z","url":null,"abstract":"<p><strong>Background: </strong>Rising medical expenditure has posed a major governance challenge worldwide, prompting health systems to replace fee-for-service reimbursement with case-based payment models to realign provider incentives. China has also implemented the case-based payment reform nationwide, adopting both the DRG-based payment and a domestically developed alternative model known as the Diagnosis-Intervention Packet (DIP). Using a county-level panel dataset from Sichuan Province covering 2011-2022, this study examines how this reform is associated with changes in hospitalization rates, an outcome that remains insufficiently understood in the existing literature.</p><p><strong>Methods: </strong>This study employs an imputation-based staggered difference-in-differences design to examine the impact of case-based payment reform on public hospital hospitalization rates.</p><p><strong>Results: </strong>The case-based payment reform increases public hospitals' hospitalization rates by 0.72% points, a 6.7% increase relative to the pre-reform mean of 10.68%. Additional analyses offer suggestive evidence on factors that may be related to this pattern. On the supply side, the reform is associated with improved hospital efficiency, which is consistent with the possibility that hospitals are able to accommodate more inpatient admissions. On the behavioral side, changes in hospitalization rates may also reflect hospitals' strategic adjustment to the new reimbursement scheme. Heterogeneity analyses further show that the effect is more pronounced in areas with more abundant medical resources, higher per capita health insurance revenue, and a lower share of beds in primary care institutions.</p><p><strong>Conclusions: </strong>Case-based payment reforms can trigger unintended volume expansion, which could partly weaken their expected cost-containment effects. These findings highlight the importance of designing provider payment systems with more carefully aligned incentives and strengthening regulatory frameworks to monitor hospitals' behavioral responses. The evidence also offers policy-relevant lessons for China and other low- and middle-income countries seeking to reform provider payment systems while balancing cost control, service capacity, and access to care.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"16 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13721392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health economic evaluation of health promotion and disease prevention in Germany: a scoping review. 德国健康促进和疾病预防的健康经济评价:范围审查。
IF 3.4 3区 经济学
Health Economics Review Pub Date : 2026-09-25 DOI: 10.1186/s13561-026-00859-0
Eva Juliane Beer, Michaela Kirschneck, Michaela Coenen, Rosa Maria Sija Visscher
{"title":"Health economic evaluation of health promotion and disease prevention in Germany: a scoping review.","authors":"Eva Juliane Beer, Michaela Kirschneck, Michaela Coenen, Rosa Maria Sija Visscher","doi":"10.1186/s13561-026-00859-0","DOIUrl":"10.1186/s13561-026-00859-0","url":null,"abstract":"<p><strong>Background: </strong>Health promotion and disease prevention are receiving increasing attention in Germany because of their potential to improve population health and reduce healthcare costs. Health-economic evaluations (HEEs) are essential for informing evidence-based decision-making in this field. However, HEEs of preventive interventions often face methodological challenges. This scoping review examines the current state and characteristics of HEEs conducted in the context of health promotion and disease prevention in Germany.</p><p><strong>Methods: </strong>A scoping review was conducted to map the landscape of HEE of health promotion and disease prevention interventions in Germany, following a priori-registered protocol. Three bibliographic databases (MEDLINE, EMBASE and Web of Science) were searched from their inception to March 2025. The screening of titles, abstracts, and full texts was performed in a blinded, double-reviewer, and stepwise manner using predefined inclusion criteria: (i) focus on the German population, (ii) application of an HEE as the primary research method, and (iii) evaluation of a health-promoting or disease-preventing intervention. Studies focusing on tertiary prevention were excluded.</p><p><strong>Results: </strong>Of the 4,632 records identified, 162 eligible original studies met the inclusion criteria. The volume of published HEEs has increased over time. Most studies (53.7%) assessed primary preventive interventions. Cost-effectiveness analysis was the most frequently applied HEE analysis type. Incremental cost-effectiveness ratios (ICERs) are commonly reported as incremental costs per quality-adjusted life year (QALY) gained (42.4% of all ICERs). In 85.2% of the studies, the intervention was judged to be cost-effective. A model-based approach was used in 75.9% of the studies, and 81.3% of these studies relied partly on non-German data sources. More than half of all studies (56.1%) reported limitations due to a lack of German-specific data.</p><p><strong>Conclusions: </strong>HEEs related to health promotion and disease prevention interventions in Germany exhibit substantial methodological heterogeneity. Frequent reliance on non-German data and the large proportion of interventions deemed cost-effective may reflect contextual data gaps and potential publication bias. These issues complicate the interpretation of economic evidence and pose challenges for decision-makers seeking to prioritize preventive strategies.</p><p><strong>Trial registration: </strong>https://osf.io/h6749/overview.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"16 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615592/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149064993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Societal cost-of-illness analysis of self-injection of biologics for patients with rheumatoid arthritis in Japan using claims, surveys, and national statistics. 更正:使用索赔、调查和国家统计数据对日本类风湿性关节炎患者自我注射生物制剂的社会疾病成本进行分析。
IF 3.4 3区 经济学
Health Economics Review Pub Date : 2026-09-24 DOI: 10.1186/s13561-026-00816-x
Kazuhiko Takahata, Eiichi Tanaka, Ryoko Sakai, Manabu Akazawa
{"title":"Correction: Societal cost-of-illness analysis of self-injection of biologics for patients with rheumatoid arthritis in Japan using claims, surveys, and national statistics.","authors":"Kazuhiko Takahata, Eiichi Tanaka, Ryoko Sakai, Manabu Akazawa","doi":"10.1186/s13561-026-00816-x","DOIUrl":"10.1186/s13561-026-00816-x","url":null,"abstract":"","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"16 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13602751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149041125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on: effects of emergency department length of stay on inpatient utilization and mortality. 评急诊科住院时间对住院利用率和死亡率的影响。
IF 3.4 3区 经济学
Health Economics Review Pub Date : 2026-09-18 DOI: 10.1186/s13561-026-00842-9
Ching-Yi Chen, Shih-Fen Tseng, Yung-Shuo Kao, Raymond Nien-Chen Kuo
{"title":"Comment on: effects of emergency department length of stay on inpatient utilization and mortality.","authors":"Ching-Yi Chen, Shih-Fen Tseng, Yung-Shuo Kao, Raymond Nien-Chen Kuo","doi":"10.1186/s13561-026-00842-9","DOIUrl":"10.1186/s13561-026-00842-9","url":null,"abstract":"<p><p>Emergency department (ED) crowding is a persistent global challenge with well-documented consequences for patient outcomes and healthcare resource utilization. A recent study by Ma et al. reported that prolonged ED length of stay was associated with lower inpatient hospitalization costs, a finding that merits careful methodological scrutiny.We outline three considerations that may inform the interpretation of these findings. First, the aggregate cost of an admitted population is sensitive to its case-mix; hospitalization costs vary substantially across and within clinical services, and the relative proportion of admissions across departments, which the study does not report across length-of-stay strata, could materially affect the cost comparison; disentangling a true departmental effect from differences in case severity and procedure intensity would require risk-adjusted, standardized cost data. The cost outcome is further limited to inpatient charges, with ED costs unmeasured, yet the Discussion attributes lower costs among longer-stay patients to resource use shifting into the ED; because ED costs were not captured, this resource-shifting mechanism is asserted rather than demonstrated, and the pattern is equally consistent with a truncated or front-loaded inpatient work-up, differential case-mix, or survivorship effects given the concurrently higher mortality in the same strata. Second, comorbidity is operationalized as a binary variable, and the counterintuitive finding of higher adjusted mortality among patients recorded as comorbidity-free may, at least in part, reflect an apparent inversion of the comorbidity labels in the original tables, the limits of administrative coding, acute severity not captured by the Elixhauser index, or residual confounding. Third, the association between prolonged stays and lower costs may partly reflect institutional bed-allocation policy rather than patient-level factors alone, because occupancy measures and allocation rules are distinct.Addressing these considerations would strengthen the causal interpretability of the findings and advance the evidence base for ED operational policy.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"16 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13587456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149002664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Return on investment from primary care price reductions in a consumer choice health plan design. 在消费者选择的健康计划设计中,初级保健价格降低的投资回报。
IF 3.4 3区 经济学
Health Economics Review Pub Date : 2026-08-14 DOI: 10.1186/s13561-026-00820-1
Tim McDonald, Bryan Dowd, Chris Whaley
{"title":"Return on investment from primary care price reductions in a consumer choice health plan design.","authors":"Tim McDonald, Bryan Dowd, Chris Whaley","doi":"10.1186/s13561-026-00820-1","DOIUrl":"10.1186/s13561-026-00820-1","url":null,"abstract":"<p><strong>Background: </strong>There is growing interest among insurers and policy makers in the United States in primary care playing an expanded role to improve quality and lower cost. These activities often are not costless for primary care practices or clinics (PCCs) to implement, and the costs are not always reimbursed. Thus, a PCC facing expectations to provide additional, unreimbursed services is likely to consider their return on investment (ROI). Additionally, when private businesses are used to implement government policy, the objectives, resources, and constraints of the businesses need to be carefully considered.</p><p><strong>Methods: </strong>We develop a general model for the PCC's ROI in a tiered cost-sharing health insurance benefit design in which PCCs with lower total risk-adjusted annual per capita cost of care (TCOC) are assigned to a tier with lower consumer cost-sharing, leading to an increase in patient volume. We focus on price discounts as one way to lower the PCC's TCOC, but the same analysis would apply to any unreimbursed effort to make the PCC more attractive to prospective patients, e.g., in a capitation system with regulated fees. We use data from a large state employee insurance program that uses such a TCOC design.</p><p><strong>Results: </strong>The study finds that discounts of 10-20 percent can have a positive ROI for the PCC, meaning a PCC may generate more income through a gain of patient volume than is lost through lowering their unit prices. These results are sensitive to the model's parameters.</p><p><strong>Conclusions: </strong>The study finds that primary care clinics offering 10-20 percent price discounts within a tiered cost-sharing insurance model can achieve a positive return on investment. Increased patient volume from lower cost-sharing tiers can offset the revenue loss from discounts. However, the profitability of these strategies depends strongly on specific model parameters and assumptions.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"16 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13757176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The societal costs of suicide - a Norwegian register-based study. 自杀的社会成本——挪威一项基于登记的研究。
IF 3.4 3区 经济学
Health Economics Review Pub Date : 2026-08-13 DOI: 10.1186/s13561-026-00843-8
Carl-Aksel Sveen, Ping Qin, Lars Mehlum, Fredrik A Walby
{"title":"The societal costs of suicide - a Norwegian register-based study.","authors":"Carl-Aksel Sveen, Ping Qin, Lars Mehlum, Fredrik A Walby","doi":"10.1186/s13561-026-00843-8","DOIUrl":"10.1186/s13561-026-00843-8","url":null,"abstract":"<p><strong>Background: </strong>Suicide constitutes a serious public health problem, leaving many more bereaved. It also represents a major economic burden to society, and the aim of this study was to estimate the societal costs of suicide in Norway.</p><p><strong>Methods: </strong>This cost-of-illness study included direct suicide-related costs and indirect costs in the form of lost economic productivity. It is the first study of suicide using individual register data on the deceased's earnings to estimate productivity losses. Estimates incorporated productivity growth and life expectancy adjustments but excluded intangible costs and unpaid work.</p><p><strong>Results: </strong>In 2018, the mean societal costs per suicide were NOK 5,510,518 (USD 634,041). Productivity losses constituted the largest cost component (98.8%), whereas direct costs only represented 1.2%. The societal costs for women were significantly lower than for men. A large proportion of those who died by suicide was outside the workforce prior to death, reducing the level of productivity losses. Individuals with prior contact with specialized mental health services had significantly lower societal costs than those without. The total societal costs of all 675 suicides in 2018 were NOK 3.7 billion (USD 428 million), corresponding to 13,548 potential productive years lost.</p><p><strong>Conclusions: </strong>The mean and total societal costs of suicide are substantial, yet lower than reported in most previous studies, as the individual, register-based data reveals low workforce participation and high levels of contact with mental health services before death. Nonetheless, the societal costs and burden of suicide underscore the need for increased development of cost-effective suicide prevention.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"16 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13757008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimorbidity burden and high-cost status among patients with diabetes: evidence from longitudinal claims data in China. 糖尿病患者的多病负担和高成本状况:来自中国纵向索赔数据的证据
IF 3.4 3区 经济学
Health Economics Review Pub Date : 2026-08-10 DOI: 10.1186/s13561-026-00841-w
Xing Chen, Luying Zhang, Wen Chen
{"title":"Multimorbidity burden and high-cost status among patients with diabetes: evidence from longitudinal claims data in China.","authors":"Xing Chen, Luying Zhang, Wen Chen","doi":"10.1186/s13561-026-00841-w","DOIUrl":"10.1186/s13561-026-00841-w","url":null,"abstract":"<p><strong>Objective: </strong>Multimorbidity is common among people with diabetes and is associated with healthcare cost concentration. This study aims to quantify multimorbidity burden and evaluates the association between multimorbidity and high-cost (HC) status.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using longitudinal health insurance claims and chronic disease management data from 79,910 diabetic patients in eastern China. Patients in the top 10% of annual healthcare expenditures in 2019 were classified as HC. Multimorbidity was defined based on 29 chronic conditions identified through literature review and utilization thresholds. Descriptive analyses compared HC and non-high-cost (NHC) patients. Six machine learning models were developed to identify the contribution of multimorbidity to HC patients, using ROC-AUC and PR-AUC as the primary performance metrics. For the best-performing model, the Shapley additive explanation (SHAP) method was used to interpret the results.</p><p><strong>Results: </strong>A total of 7,991 (10.0%) patients were classified as HC. HC patients had a higher multimorbidity burden than NHC patients (mean number of conditions: 8.6 vs. 6.4). Mean annual expenditure was substantially higher among HC patients ($25,903 vs. $2,490). Multimorbidity-related care accounted for 33.6% of total expenditures and was over ten times higher in HC patients. Hypertension was the most prevalent condition among HC patients (91.3%), while cerebrovascular disease sequelae generated the highest per-patient costs ($8,869). The Extreme Gradient Boosting model achieved the best performance (ROC-AUC = 0.750, PR-AUC = 0.301). SHAP analysis identified cerebrovascular disease sequelae, renal failure, chronic ischemic heart disease, cerebral infarction and osteoporosis as the most influential predictors of multimorbidity affecting HC status.</p><p><strong>Conclusions: </strong>Multimorbidity is associated with HC status of patients with diabetes. Strengthening risk stratification and integrated management for patients with cardiovascular, cerebrovascular, renal, and skeletal diseases can help reduce healthcare costs and improve health outcomes.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"16 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13741715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149358153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书